Liminal BioSciences  logo
Liminal BioSciences LMNL
report update icon

Quarterly report 2023-Q2
added 05-23-2026

Liminal BioSciences Financial Statements 2022-2011 | LMNL

Annual Financial Statements Liminal BioSciences

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 2.65 M 11.7 M 133 M 248 M 876 M 971 M 1.03 B 867 M 612 M 130 K -

Shares

3.1 M 3.02 M 2.44 M 16.1 M 828 K 796 K 598 K 571 K 578 K 490 K 420 K -

Historical Prices

- 0.88 4.8 8.25 299 1.1 K 1.8 K 1.95 K 1.98 K 1.4 K 457 113

Net Income

622 K 12.2 M -119 M -207 M -238 M -120 M -101 M -51 M 5.94 M -16.5 M 230 K -2.55 M

Revenue

401 K 643 K 724 K 745 K 24.6 M 22.3 M 16.4 M 24.5 M 23 M 20.6 M 23.3 M 17.6 M

Gross Profit

- - 1.28 M 2.14 M -1.07 M 29 M 9.63 M 16.3 M 16 M 14 M 18 M 15.7 M

EBITDA

- - -85.6 M -213 M -226 M -123 M -109 M -57.3 M -15.1 M -16.3 M 2 M -930 K

Operating Expenses

- - 95.4 M 120 M 123 M 152 M 117 M 66.8 M 48.1 M 27.1 M 16.3 M 17.2 M

General and Administrative Expenses

- - 38.6 M 45.3 M 29.4 M 29.6 M 29.3 M 16.6 M 12.1 M 8.58 M 5.97 M 5.79 M

All numbers in CAD currency

Quarterly Income Statement Liminal BioSciences

2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

3.1 M 3.1 M - 31 M - 3.02 M - 29.9 M - 2.44 M - 23.4 M - 16.1 M - 16.5 M - 828 K - - - 796 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-9.14 M 622 K - -6.22 M - 12.2 M - -32.1 M - -119 M - -27.8 M - -207 M - -134 M - -238 M - - - -120 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 401 K - - - 643 K - - - 724 K - 540 K - 745 K - 762 K - 24.6 M - - - 22.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - - - - - 38.6 M - 9.85 M - 45.3 M - 18 M - 29.4 M - - - 29.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Liminal BioSciences LMNL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Liminal BioSciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.64 5.92 % $ 691 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.99 4.33 % $ 255 M usaUSA
Alector Alector
ALEC
$ 2.19 2.1 % $ 226 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 5.08 0.96 % $ 50.2 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 45.83 0.22 % $ 7.55 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.79 0.28 % $ 395 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 248.37 0.14 % $ 32.5 B usaUSA
Altimmune Altimmune
ALT
$ 3.31 1.22 % $ 292 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.93 0.52 % $ 104 M usaUSA
Amgen Amgen
AMGN
$ 380.17 0.75 % $ 205 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 23.96 0.74 % $ 1.12 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.02 1.59 % $ 5.82 B irlandaIrlanda
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 17.23 1.29 % $ 5.4 B usaUSA
AbbVie AbbVie
ABBV
$ 261.94 1.87 % $ 463 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 54.77 1.67 % $ 1.58 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.22 1.7 % $ 304 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 70.92 1.04 % $ 1.42 B usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.76 2.03 % $ 4.97 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.87 2.75 % $ 590 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.04 1.38 % $ 3.3 B canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.89 2.41 % $ 523 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 15.23 3.39 % $ 417 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 3.54 0.14 % $ 853 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.3 1.84 % $ 192 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.35 1.95 % $ 3.1 B usaUSA
Artelo Biosciences Artelo Biosciences
ARTL
$ 5.15 1.1 % $ 974 K usaUSA
Arvinas Arvinas
ARVN
$ 8.44 0.41 % $ 598 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 80.24 0.11 % $ 10.7 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.86 0.64 % $ 324 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.25 6.87 % $ 39 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 9.49 1.17 % $ 119 M usaUSA
Agenus Agenus
AGEN
$ 7.12 2.59 % $ 212 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.3 1.26 % $ 2.19 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.94 2.93 % $ 516 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 5.34 0.47 % $ 435 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 491.2 2.47 % $ 38.4 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 216.73 0.75 % $ 10.8 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.0 0.5 % $ 12.6 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 72.33 0.1 % $ 13.9 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.2 0.92 % $ 1.72 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.87 0.13 % $ 268 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.03 2.52 % $ 115 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 24.35 1.5 % $ 2.41 B usaUSA
Biogen Biogen
BIIB
$ 217.62 0.22 % $ 31.9 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.48 0.2 % $ 6.11 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.22 0.82 % $ 12.7 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 64.03 0.61 % $ 130 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.11 0.08 % $ 498 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.35 1.13 % $ 953 M britainBritain